(Circulation. 1997;96:2612-2616.)
© 1997 American Heart Association, Inc.
Articles |
From the Division of Cardiology (Y.A., M.F., T.Y., M.O., T.S., K.K., J.K., S.S., N.H.), Osaka Prefectural Hospital, and The 1st Internal Medicine (M.H.), Osaka University Medical School, Osaka, Japan.
| Abstract |
|---|
|
|
|---|
Methods and Results One hundred twenty-two consecutive
patients with PAF were prospectively followed after P-SAE,
echocardiography, and 24-hour Holter monitoring at
study entry. The duration (Ad) and root-mean-square voltage for the
last 30 ms (LP30) of the filtered P wave were measured in P-SAE. The
abnormality of P-SAE for the prediction of transition to CAF was
defined as Ad
145 ms and LP30 <3.0 µV. Twenty-three (19%; group
1) of the patients had the abnormality of P-SAE, whereas the others
(group 2) did not. During the follow-up period (mean, 26±12 months),
10 patients (43%) in group 1 acquired CAF, whereas the transition to
CAF was observed in only 4 patients (4%) in group 2. Kaplan-Meier
analysis revealed that the transition to CAF was significantly
observed more often in group 1 than in group 2 (log-rank test,
P<.0001). The Cox proportional hazards regression model
identified that the variables most significantly associated with
the transition to CAF were Ad (
2=8.6,
P=.003) and LP30 (
2=5.1,
P=.02), although significant differences in the left atrial
dimension (40.8±5.3 versus 37.3±5.5 mm, P<.01) and
the number of atrial premature contractions (3641±4524 versus
1489±2895 beats/d, P<.05) were observed between groups 1
and 2.
Conclusions These results indicate that P-SAE could be useful to identify patients at risk for the transition from PAF to CAF.
Key Words: atrium fibrillation electrocardiography follow-up studies
| Introduction |
|---|
|
|
|---|
There have been no definite methods to predict the transition from PAF to CAF, so the purpose of this study was to determine prospectively whether the transition from PAF to CAF could be predicted by the use of P-SAE, which we recently reported to be useful to identify the patients at risk for PAF during sinus rhythm.11 12
| Methods |
|---|
|
|
|---|
1 µV in the composite lead of P-SAE (5 patients), (2) it was
difficult to determine the end of the filtered P wave because of too
short PQ intervals (9 patients), or (3) the patient was taking an
antiarrhythmic agent that could affect the results of P-SAE (2
patients). In addition, 11 patients who did not give consent to the
follow-up period were excluded from a prospective analysis. A
total of 122 patients were enrolled in this study. The study patients were followed for 26±12 months (range, 6 to 38 months) after the entry, defined as the time of P-SAE. The interval from the first symptomatic episode, such as palpitation, to entry was 14±21 months in patients with symptomatic PAF attacks. The mean age of 122 patients was 61±12 years at entry. There were 77 men and 45 women. Fifty patients had no organic heart disease, and the remaining 72 patients had organic heart disease or another disease that possibly caused PAF (30 patients with ischemic heart disease, 14 with hypertension or hypertensive heart disease, 16 with valvular heart disease, 9 with pericardial or myocardial disease, 2 with congenital heart disease, and 1 with hyperthyroidism).
P-SAE
P-SAE was performed in all patients at the entry. The
methodology of P-SAE recording and analysis has been
described previously.11
The P-SAE was recorded from a modified X, Y, and Z lead system using the VCM-3000 (Fukuda Densi, Ltd). All of the digital data were stored on a floppy disk. The standard I lead was used as the X lead, the aVF lead was used as the Y lead, and the precordial V1 lead was used as the Z lead. The signal from each lead was amplified up to 5 µV/cm, passed through a low-pass filter of 300 Hz (slope, 12 dB/oct) and a high-pass filter of 40 Hz (slope, 18 dB/oct), and then converted from analog to digital data to a 12-bit accuracy at the sampling rate of 1 kHz.
A specially filtered P wave derived from the selected dominant sinus P wave of the standard II or V1 lead served as a reference signal for all processing. The specially filtered P wave was obtained with a band-pass filter of 10 to 30 Hz. The method of P-wavetriggered signal-averaging mainly involved three processes: (1) preparation of the template, (2) template matching, and (3) fine adjustment of the trigger point.
Preparation of Template
The template of the filtered P wave was made from the selected
sinus P wave. The voltage was measured every 2 ms (31 points) from 30
ms before to 30 ms after the first peak of the specially filtered P
wave; then, the specially filtered P wave was standardized so the total
amplitude in this interval could be 250. We determined this wave in
this window of the standardized filtered P wave as the template.
Template Matching (by a Difference Method)
A peak voltage of each specially filtered P wave was compared
with the peak voltage of the template. Whenever the peak voltage of
each specially filtered P wave was <70% of the template, the P wave
was automatically rejected. Subsequently, the difference between each
standardized P wave and the template was measured every 2 ms from 30 ms
before to 30 ms after the adjusted trigger point of the specially
filtered P wave. Whenever the sum [
X(template)i-Xi
(1
i
31)] of
the differences in 31 of these points in this window was >1024, the P
wave was also automatically rejected; the number 1024 was determined in
a preliminary experimental study so signal-averaging could be more
precisely and quickly performed. If the number was <1024, it took
longer to perform signal-averaging. Conversely, if the number was
>1024, there was the fear that signals other than sinus P wave might
be included.
Fine Adjustment of Trigger Point
Although the trigger point of signal-averaging had been
determined around the first peak of the specially filtered P wave in
advance, we finely adjusted the point in the following to make the
triggering jitter least. Template matching was repeated with a fiducial
point every 1 ms around the first peak of the specially filtered P
wave. The trigger point was adjusted so the sum of differences in this
window between each standardized P wave and the template might be
minimized. The signals of 200 beats, which had already been filtered,
were averaged on this trigger point within the specially filtered P
wave. If the noise level remained >1 µV even after the averaging of
200 beats, averaging was continued until the peak noise level was
reduced to <1 µV. The filtered signals for the X, Y, and Z leads
were combined into a spatial magnitude:
(X2+Y2+Z2)1/2. The
onset and offset of the filtered P wave were defined as signals during
the interval when signals show a persistent level of 1 µV. Ad and
LP10, LP20, and LP30 for the last 10, 20, and 30 ms of filtered P wave
were measured in the vector magnitude.
In our previous retrospective study,13 the SAE
variables had been scrutinized for specific criteria indicating a
risk of CAF in patients with PAF. The criteria had been defined as Ad
145 ms and LP30 <3.0 µV; therefore, these criteria were used in
this study to predict the risk for CAF.
Echocardiographic Measurement
Echocardiography was also performed in all
patients at entry (Toshiba SSH-160A recorder equipped with 2.5- or
3.5-MHz transducers). The standard technique14 was used
for sizing of the left ventricle. Left ventricular
dimensions were measured at end diastole, recognized for
the peak of the R wave of the ECG, and at end systole, just below the
mitral leaflets through the standard left parasternal window.
Transducer position was aided by the two-dimensional echo mode, and the
left ventricular ejection fraction was calculated according
to Gibson's method. Furthermore, the left atrial dimension was
measured as a distance from the leading edge of the posterior aortic
wall to the leading edge of the posterior left atrial wall at end
systole.
Holter Monitoring
In 82 of 122 patients, 24-hour ambulatory Holter ECG
recordings were also obtained at entry. Analysis was
performed using a Marquette Electronics 8000 Holter monitoring system,
and the number of atrial premature contractions was counted for 24
hours.
Follow-up and Definition of CAF
All patients were followed up at least every month and examined
by ECG or portable ECG monitoring to observe the cardiac rhythm. CAF
was defined as atrial fibrillation sustained for
6 months. The
results of P-SAE were blinded to the primary physicians taking care of
the patients and did not in any way influence therapeutic decision. The
use of antiarrhythmic agents (type and dosage) after the entry was left
to the discretion of the primary physicians.
Statistical Analysis
Data are presented as mean±SD. Statistical
analysis was performed using Student's t test to
compare patients with and without the abnormality of P-SAE. The event
(CAF)-free rates in patients with and without the abnormality of P-SAE
were calculated using the Kaplan-Meier method, and the difference
between them was detected using the log-rank test. The determination of
the prognostic significance of abnormal results on P-SAE,
echocardiography, and Holter monitoring was
explored by survival analysis based on the Cox proportional
hazards regression model. The level of significance was determined at a
value of P=.05.
| Results |
|---|
|
|
|---|
145 ms and LP30 <3.0 µV. Twenty-three
patients had the abnormality of P-SAE (group 1), whereas the other 99
patients (group 2) did not. Fig 1
|
Prediction of Transition to CAF by P-SAE
There was no difference in follow-up period between groups 1 and 2
(25±13 versus 26±11 months). Ten patients (43%) in group 1 acquired
CAF, whereas the transition to CAF was observed in only 4 patients
(4%) in group 2. Patients with the abnormality of P-SAE had an 11-fold
risk of transition to CAF. Fig 2
shows
the event (CAF)-free rate curve according to Kaplan-Meier
analysis. In group 1, the CAF-free rate was 89% for 1 year and
38% for 3 years; in group 2, the CAF-free rate was 94% for 3 years.
The transition to CAF in group 1 was significantly more frequently
observed than in group 2 (P<.0001). Accordingly, abnormal
findings of P-SAE gave a sensitivity of 71%, a specificity of 88%, a
positive predictive value of 43%, and a negative predictive value of
96% for the prediction of transition to CAF.
|
The stepwise Cox survivorship analysis was used with regression
covariates to determine the prognostic power of clinical variables
(age, sex, presence of organic heart disease, and use of any
antiarrhythmic agents) and noninvasive variables in P-SAE,
echocardiography, and 24-hour Holter monitoring. Ad
(
2=8.6, P=.003), LP30
(
2=5.1, P=.02), and age
(
2=4.9, P=.03) had the most
significant relation to the transition to CAF, although Ad correlated
with LP30 (r=-.374, P=.0001).
Comparison Between Patients With and Without the Transition to
CAF
During the follow-up period (26±12 months; range, 6 to 38
months), the transition from PAF to CAF was observed in 14 of 122
patients (11%) (CAF group), and the other 108 patients continued to
have PAF (PAF group). The clinical characteristics of the CAF and PAF
groups are given in Table 2
.
There were no significant differences in sex, age, and presence of
organic heart disease between the CAF and PAF groups. Ad in the CAF
group was significantly longer than that in the PAF group (162.7±19.8
versus 137.8±13.4 ms, P<.0001). Furthermore, there were
significant differences in LP10, LP20, and LP30 between the two groups
(LP10, 1.5±0.3 versus 1.9±0.7 µV, P<.05; LP20, 1.9±0.7
versus 2.6±1.1 µV, P<.05; and LP30, 2.5±0.8 versus
4.0±1.8 µV, P<.005).
Echocardiographically, left atrial dimension in the CAF
group was significantly larger than that in the PAF group (40.5±5.1
versus 36.4±5.2 mm, P<.05), although no significant
differences in left ventricular dimensions measured at end
diastole and end systole and ejection fraction were
observed between the two groups. In 24-hour Holter monitoring, the
number of atrial premature contractions for 24 hours in the CAF group
(n=8) tended to be more than those in the PAF group (n=74) (3457±3848
versus 1741±3283 beats/d, P=.17).
|
| Discussion |
|---|
|
|
|---|
Abnormality of P-SAE for Prediction of Transition to CAF
In our previous study,13 the signal-averaged ECG
variables were scrutinized for specific criteria indicating a risk
of CAF in patients with PAF. The P-SAE values of 14 patients who had
accomplished CAF after undergoing P-SAE at the time of diagnosis of PAF
were retrospectively compared with those of 68 patients who remained in
PAF. Ad was significantly longer and the terminal portions of filtered
P wave (LP10, LP20, and LP30) were significantly lower in 14 patients
who had the transition to CAF than in the 68 patients who remained in
PAF. When the criterion of Ad
145 ms was used, the sensitivity,
specificity, and predictive accuracy values were 86%, 71%, and 80%,
respectively; when the criterion of LP30 <3.0 µV was used, the
sensitivity, specificity, and predictive accuracy values were 79%,
71%, and 72%, respectively. When the criteria of Ad
145 ms and LP30
<3.0 µV were combined, the values became 71%, 91%, and 89%,
respectively. Therefore, the criteria of Ad
145 ms and LP30 <3.0
µV were used in this study to predict the risk for CAF.
Prediction of Transition to CAF
To our knowledge, there have been no published data regarding the
methodology of detection of the risk for CAF. Takahashi et
al3 reported that patients with the establishment of
atrial fibrillation had more frequent and longer atrial fibrillation
attacks than did those in whom the attacks remained paroxysmal. We
previously reported17 that the filtered P-wave duration in
patients with more frequent attacks (once a month or more often) was
significantly longer than that in those with less frequent attacks
(140.2±13.6 versus 130.8±11.1 ms), whereas there was no significant
relation between the duration of PAF attacks and filtered P wave. In
this study, 107 patients had symptomatic PAF attacks when
the atrial fibrillation was documented in our hospital. However, PAF
could not be documented in some patients when they had symptoms such as
palpitation. Therefore, we investigated 57 patients who had documented
PAF at least twice with symptom after entry. Four patients in group 1
and 23 patients in group 2 had a high frequency (once a month or more
often) of PAF attacks at entry. On the other hand, 5 patients in group
1 and 26 patients in group 2 had longer (
2 hours) PAF attacks. There
were no significant differences in frequency
(
2=1.9, P=.17) and duration
(
2=1.7, P=.19) of PAF attacks between
the two groups in this study.
The Framingham Study reported18 that left ventricular function was one of determinants of CAF. In the present study, however, there was no significant difference in left ventricular function measured by echocardiography between the CAF and PAF groups. The difference between the Framingham Study and the present study could be due to patient characteristics. In the present study, only outpatients who had maintained cardiac function relatively well were studied; most of the study patients had normal left ventricular function. Therefore, it is difficult to determine whether left ventricular function could be an important risk factor for CAF.
Pathophysiology of P-WaveDuration Prolongation
Some investigators reported that patients with a history of atrial
fibrillation had long signal-averaged P waves. Stafford et
al19 tried to quantify differences in the fine morphology
of P waves in a group of 9 patients with PAF versus 15 control
subjects. They found signal-averaged P-wave duration was significantly
increased in patients with PAF. Similarly, Guidera and
Steinberg18 reported the filtered P-wave duration was
longer in patients with a history of atrial fibrillation than in age-
and disease-matched control subjects. We succeeded in detecting
patients at risk for PAF during sinus rhythm by using
P-SAE11 and discovered that filtered P-wave duration was
significantly longer in patients with PAF than in control subjects. In
this study, we observed that the patients with PAF who eventually
developed CAF had further prolonged filtered P-wave duration compared
with the patients who did not develop CAF. These results suggest that
the conduction in atrium might be more severely disturbed in patients
with CAF than in those with PAF, although this is highly
speculative.
Clinical Implication of Prediction of Transition to CAF
It was clinically significant to predict the transition to CAF in
patients with PAF because of the two following viewpoints. First, it
was reported that mortality was higher in patients with CAF than in
those with PAF regardless of the presence of underlying heart
disease.7 Second, it was reported5 6 8 9 10
that the risk of thromboembolism was higher in patients with CAF than
in those with PAF. In this study, 2 patients (14%) in the CAF group
had systemic embolism during the follow-up period, whereas 2 patients
(2%) in the PAF group had it; patients in the CAF group had a 7-fold
risk of embolism compared with patients in the PAF group. Therefore,
the patients with PAF who were at risk of CAF should have more frequent
surveillance and possibly a more aggressive approach to the treatment
of thromboembolism and their underlying heart diseases or a
prophylactic intervention for atrial fibrillation.
Study Limitations
First, because a PQ interval that is too short may mask the
true end of filtered P wave in the initial portion of QRS complex in
P-SAE, the end point of the filtered P wave could not be decided due to
the overlap. However, if the filtered P wave intersected the QRS
complex, we could analyze it as a tentative P wave from the
onset of the P wave to the onset of the QRS complex. In this study, all
9 patients with a short PQ interval maintained PAF without a transition
to the chronic stage. They would become classified into group 2 because
of their relatively short P-wave duration. For these 9 patients,
specificity would improve to 89%. Second, in this study, drug therapy
was not controlled, so we could not precisely determine the influence
of antiarrhythmic drugs in the transition to CAF. However, the primary
physicians did not know the results of P-SAE, and there were no
significant differences in the use of antiarrhythmic agents between the
patients with and those without the abnormality of P-SAE. Third, in
most of the patients, antiarrhythmic agents were administered to
prevent PAF attacks after performance of control P-SAE on
entry. This is why we were unable to analyze the serial change
of P-SAE until the acquisition of CAF; the effect of antiarrhythmic
agents on P-SAE was widely variable. However, the extent of the
change in P-SAE due to the drugs could possibly reflect the risk of the
transition from PAF to CAF. Further studies will be needed the resolve
this matter. Fourth, the positive predictive value was low (43%);
false-positives might be reduced by further studies that include
optimal filtering. Fifth, in this study, we studied only consecutive
outpatients who had maintained cardiac function, unlike inpatients. On
this point, we can not overlook the bias in patient characteristics;
therefore, further studies are needed to investigate patients with PAF
who have clinical characteristics that differ from those of our
patients.
Conclusions
In this study, we reported that patients with the
abnormality of P-SAE had an 11-fold risk of the transition to CAF in
comparison with those without the abnormality. These findings suggest
that P-SAE was useful to predict the transition to CAF in patients with
PAF.
| Selected Abbreviations and Acronyms |
|---|
|
|
|
| Footnotes |
|---|
Received January 21, 1997; revision received May 12, 1997; accepted May 28, 1997.
| References |
|---|
|
|
|---|
2. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR, Ilstrup DM, Frye RL. The natural history of lone atrial fibrillation: a population-based study over three decades. N Engl J Med. 1987;317:669-674.[Abstract]
3. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation: an observation of 94 patients. Jpn Heart J. 1981;22:143-149.[Medline] [Order article via Infotrieve]
4. Suttorp MJ, Kingma JH, Koomen EM, van'tHof A, Tijssen JGP, Lie KIL. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol. 1993;71:710-713.[Medline] [Order article via Infotrieve]
5. Peterson P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke. 1986;622-626.
6. Wiener I. Clinical and echocardiographic correlates of systemic embolization in non rheumatic atrial fibrillation. Am J Cardiol. 1987;59:177.[Medline] [Order article via Infotrieve]
7.
Gajewski J, Singer RB. Mortality in insured
population with atrial fibrillation. JAMA. 1981;245:1540-1544.
8. Treseder AS, Sastry BSD, Thomas TPL, Yates MA, Pathy MS. Atrial fibrillation and stroke in elderly hospitalized patients. Age Ageing. 15:89-92,1986.
9. Petersen P, Godtfredsen J. Atrial fibrillation: a review of course and prognosis. Acta Med Scand. 1984;216:5-9.[Medline] [Order article via Infotrieve]
10. Godtfredsen J. Atrial Fibrillation: Etiology, Course and Prognosis: A Follow-up Study of 1212 Cases. Copenhagen, Denmark: Munksgaard; 1975.
11.
Fukunami M, Yamada T, Ohmori M, Kumagai K, Umemoto K,
Sakai A, Kondoh N, Minamino T, Hoki N. Detection of patients at
risk for paroxysmal atrial fibrillation during sinus rhythm by P
wavetriggered signal-averaged
electrocardiogram. Circulation. 1991;83:162-169.
12. Yamada T, Fukunami M, Ohmori M, Kumagai K, Sakai A, Kondoh N, Minamino T, Hoki N. Characteristics of frequency content of atrial signal-averaged electrocardiograms during sinus rhythm in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1992;19:559-563.[Abstract]
13. Abe Y, Fukunami M, Ohmori M, Kumagai K, Yamada T, Nishikawa N, Hoki N. Prediction of transition from paroxysmal atrial fibrillation by P wavetriggered signal-averaged electrocardiogram. Circulation. 1993;88(suppl II):II-312. Abstract.
14. Feigenbaum H, ed. Echocardiography. Philadelphia, Pa: Lea & Febiger; 1981.
15.
Ostrander LD, Brandt RL, Kjelsberg MO, Epstein
FH. Electrocardiographic findings among the adult population of
a total natural community, Tecumseh, Michigan.
Circulation. 1965;31:888-897.
16. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983;106:389-396.[Medline] [Order article via Infotrieve]
17. Iwakura K, Abe Y, Ohmori M, Yamada T, Kondoh N, Minamino T, Tsujimura E, Fukunami M. Relationship between frequency and duration of paroxysmal atrial fibrillation attacks and atrial late potential. Circulation. 1992;86(suppl I):I-130. Abstract.
18. Kannel WB, Abbott RD, Savage DD, McNamaraPM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022.[Abstract]
19. Stafford PJ, Turner I, Vincent R. Quantitative analysis of signal-averaged P waves in idiopathic paroxysmal atrial fibrillation. Am J Cardiol. 1991;68:751-755.[Medline] [Order article via Infotrieve]
20. Guidera SA, Steinberg JS. The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol. 1993;21:1645-51.[Abstract]
This article has been cited by other articles:
![]() |
M. Bollu, R. K. Bobba, and E. L. Arsura Treatment With Amiodarone to Prevent Atrial Fibrillation JAMA, March 11, 2009; 301(10): 1019 - 1020. [Full Text] [PDF] |
||||
![]() |
F. G. Cosío, J.#x. Palacios, A.#x.;n Pastor, and A. Núñez CHAPTER 2 The Electrocardiogram ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Budeus, M. Hennersdorf, O. Felix, K. Reimert, C. Perings, H. Wieneke, R. Erbel, and S. Sack Prediction of atrial fibrillation in patients with cardiac dysfunctions: P wave signal-averaged ECG and chemoreflexsensitivity in atrial fibrillation Europace, August 1, 2007; 9(8): 601 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jideus, P. Blomstrom, L. Nilsson, M. Stridsberg, P. Hansell, and C. Blomstrom-Lundqvist Tachyarrhythmias and triggering factors for atrial fibrillation after coronary artery bypass operations Ann. Thorac. Surg., April 1, 2000; 69(4): 1064 - 1069. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamada, M. Fukunami, T. Shimonagata, K. Kumagai, H. Ogita, Y. Asano, A. Hirata, M. Hori, and N. Hoki Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study J. Am. Coll. Cardiol., February 1, 2000; 35(2): 405 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.G. Platonov, J. Carlson, M.P. Ingemansson, A. Roijer, A. Hansson, L.V. Chireikin, and S.B. Olsson Detection of inter-atrial conduction defects with unfiltered signal-averaged P-wave ECG in patients with lone atrial fibrillation Europace, January 1, 2000; 2(1): 32 - 41. [Abstract] [PDF] |
||||
![]() |
T. Yamada, M. Fukunami, T. Shimonagata, K. Kumagai, S. Sanada, H. Ogita, Y. Asano, M. Hori, and N. Hoki Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation Eur. Heart J., February 1, 1999; 20(3): 211 - 220. [Abstract] [PDF] |
||||
![]() |
H. Sakamoto, M. Kurabayashi, R. Nagai, J. Fujii, M. Fukunami, Y. Abe, and N. Hoki Prediction of Transition to Chronic Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation • Response Circulation, September 8, 1998; 98(10): 1045 - 1046. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |